Skip to main content
. 2016 Aug 9;7(10):884–889. doi: 10.1021/acsmedchemlett.6b00188

Table 1. Initial Profile for the Fragment Hit 1.

entry sPLA2-IIa IC50 (μM) plasma ICu,50 (μM)a Fu (%) LE/LLEb
varespladib 0.028 0.008 12.5 0.37/7.2
1 24 0.9 1.8 0.39/2.2
a

Calculated as plasma sPLA2 IC50 (μM) × compound’s unbound fraction in human plasma (Fu)/100. Fu = 100 – human protein binding (%).

b

Ligand efficiency, LE (kcal/mol/HAC), calculated as −RT ln(sPLA2-IIa IC50)/heavy atom count. Ligand lipophilicity efficiency (LLE) calculated as pIC50 (sPLA2-IIa) – logD.